Bank of India Mid Cap Fund
Direct · GrowthAI Summary
Bank of India Mid Cap Fund delivered a 1Y SIP XIRR of 12.28%, which trails the category average SIP XIRR of 16.0% by 3.72 percentage points. On a lump-sum basis, the fund's 1Y CAGR of 2.09% outpaced the NIFTY MIDCAP 150's -0.18%, generating positive alpha of 1.42% over the 1Y period. However, alpha turns negative over longer horizons, at -0.55% over 3Y and -0.70% over 5Y, indicating benchmark underperformance on a risk-adjusted lump-sum basis over extended periods.
The fund exhibits defensive characteristics with a beta of 0.87 against the NIFTY MIDCAP 150, capturing only 89.19% of upside and 86.81% of downside over 1Y. Only one drawdown event exceeding 10% was recorded, with a maximum drawdown of -12.49% that recovered in 37 days after a 140-day drawdown duration. The 1Y Calmar ratio of 0.43 suggests modest risk-adjusted returns, consistent with the fund's lower-volatility, lower-capture profile.
The portfolio is diversified across 50 holdings, with the top 10 positions totaling roughly 36.6% of NAV, led by Abbott India (5.28%) and Aurobindo Pharma (5.11%). Pharmaceuticals & Biotechnology is the largest sector at 13.9%, followed by Capital Markets at 7.5% and Auto Components at 6.8%, indicating moderate sector concentration with meaningful financial services exposure across banks, insurance, and capital markets. The spread across pharma, telecom, cement, oil, and metals provides reasonable diversification beyond the top sectors.
The fund's 1Y SIP XIRR of 12.28% sits well below the category average of 16.0%, and the gap is likely wider over longer horizons given category SIP XIRR averages of 19.83% (3Y) and 20.45% (5Y) versus the fund's negative long-term alpha versus its benchmark. Its below-1 beta and lower capture ratios position it as a relatively defensive mid-cap offering rather than a high-octane performer. Calendar year returns of 4.47% in 2026 and -1.4% in 2025 suggest muted but contained performance in recent periods.
This fund may suit conservative mid-cap investors who prioritize downside protection and lower volatility over maximum upside participation, given its beta of 0.87 and downside capture of 86.81%. A long time horizon of at least 5-7 years is appropriate for mid-cap exposure, though investors should recognize the fund has lagged both its benchmark over longer windows and its category on SIP returns. It is best considered as a defensive satellite allocation rather than a core mid-cap holding for investors seeking category-leading growth.
- Positive 1Y alpha of 1.42% with lump-sum CAGR of 2.09% versus benchmark's -0.18%, showing recent benchmark outperformance
- Defensive risk profile with beta of 0.87 and downside capture of 86.81%, cushioning losses in weak markets
- Diversified 50-stock portfolio with the top holding at only 5.28% of NAV, limiting single-stock concentration risk
- 1Y SIP XIRR of 12.28% significantly trails the category average of 16.0%, indicating below-peer SIP performance
- Negative alpha over 3Y (-0.55%) and 5Y (-0.70%) horizons shows persistent long-term benchmark underperformance
- Upside capture of 89.19% means the fund participates meaningfully less in mid-cap rallies, capping growth potential
Generated on 20-10-2026, 3:09 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.65 L | 12.3% | 5.4% | 19.4% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY MIDCAP 150 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 12.3% | 21.9% | 16.0% | -9.6% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 5.3% | 5.1% | 1.9% | 9.8% | -0.54 | -0.52 | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY MIDCAP 150
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +1.42 | 0.87 | 89.2% | 86.8% | 2.1% | -0.2% |
| 3 Years | -0.55 | 0.86 | 86.2% | 84.5% | 1.2% | 1.0% |
| 5 Years | -0.70 | 0.86 | 86.2% | 84.5% | 0.7% | 0.6% |
| 7 Years | -0.77 | 0.86 | 86.2% | 84.5% | 0.5% | 0.4% |
| 10 Years | -0.81 | 0.86 | 86.2% | 84.5% | 0.4% | 0.3% |
| 12 Years | -0.83 | 0.86 | 86.2% | 84.5% | 0.3% | 0.3% |
| 15 Years | -0.86 | 0.86 | 86.2% | 84.5% | 0.2% | 0.2% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Abbott India Limited | 5.28% |
| 2 | Aurobindo Pharma Limited | 5.11% |
| 3 | Bharti Hexacom Limited | 4.75% |
| 4 | Indian Bank | 3.84% |
| 5 | Multi Commodity Exchange of India Limited | 3.74% |
| 6 | Max Financial Services Limited | 2.99% |
| 7 | JK Cement Limited | 2.83% |
| 8 | UNO Minda Limited | 2.81% |
| 9 | Oil India Limited | 2.76% |
| 10 | Lloyds Metals And Energy Limited | 2.51% |